Print

PACTG 230

A phase I study to evaluate the safety and immunogenicity of recombinant HIV-1 envelope antigen in children born to HIV-infected mothers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID)
rgp120/HIV-1 SF-2,AIDSVAX B/E Protein Env B; Protein Env B/E
AIDSVAX B/E Protein
rgp120/HIV-1 SF-2 Protein
USA 183
http://www.actis.org; www.clinicaltrials.gov http://www.actis.org; www.clinicaltrials.gov